IBDEI041 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,1356,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1356,1,3,0)
 ;;=3^Acute hepatitis B w/o delta-agent and without hepatic coma
 ;;^UTILITY(U,$J,358.3,1356,1,4,0)
 ;;=4^B16.9
 ;;^UTILITY(U,$J,358.3,1356,2)
 ;;=^5000540
 ;;^UTILITY(U,$J,358.3,1357,0)
 ;;=B19.10^^3^41^108
 ;;^UTILITY(U,$J,358.3,1357,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1357,1,3,0)
 ;;=3^Viral hepatitis B without hepatic coma,unspec
 ;;^UTILITY(U,$J,358.3,1357,1,4,0)
 ;;=4^B19.10
 ;;^UTILITY(U,$J,358.3,1357,2)
 ;;=^5000552
 ;;^UTILITY(U,$J,358.3,1358,0)
 ;;=B18.1^^3^41^47
 ;;^UTILITY(U,$J,358.3,1358,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1358,1,3,0)
 ;;=3^Chronic viral hepatitis B without delta-agent
 ;;^UTILITY(U,$J,358.3,1358,1,4,0)
 ;;=4^B18.1
 ;;^UTILITY(U,$J,358.3,1358,2)
 ;;=^5000547
 ;;^UTILITY(U,$J,358.3,1359,0)
 ;;=B17.10^^3^41^6
 ;;^UTILITY(U,$J,358.3,1359,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1359,1,3,0)
 ;;=3^Acute hepatitis C without hepatic coma
 ;;^UTILITY(U,$J,358.3,1359,1,4,0)
 ;;=4^B17.10
 ;;^UTILITY(U,$J,358.3,1359,2)
 ;;=^5000542
 ;;^UTILITY(U,$J,358.3,1360,0)
 ;;=B18.2^^3^41^48
 ;;^UTILITY(U,$J,358.3,1360,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1360,1,3,0)
 ;;=3^Chronic viral hepatitis C
 ;;^UTILITY(U,$J,358.3,1360,1,4,0)
 ;;=4^B18.2
 ;;^UTILITY(U,$J,358.3,1360,2)
 ;;=^5000548
 ;;^UTILITY(U,$J,358.3,1361,0)
 ;;=B18.9^^3^41^49
 ;;^UTILITY(U,$J,358.3,1361,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1361,1,3,0)
 ;;=3^Chronic viral hepatitis, unspecified
 ;;^UTILITY(U,$J,358.3,1361,1,4,0)
 ;;=4^B18.9
 ;;^UTILITY(U,$J,358.3,1361,2)
 ;;=^5000550
 ;;^UTILITY(U,$J,358.3,1362,0)
 ;;=A69.20^^3^41^79
 ;;^UTILITY(U,$J,358.3,1362,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1362,1,3,0)
 ;;=3^Lyme disease, unspecified
 ;;^UTILITY(U,$J,358.3,1362,1,4,0)
 ;;=4^A69.20
 ;;^UTILITY(U,$J,358.3,1362,2)
 ;;=^5000375
 ;;^UTILITY(U,$J,358.3,1363,0)
 ;;=A51.0^^3^41^91
 ;;^UTILITY(U,$J,358.3,1363,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1363,1,3,0)
 ;;=3^Primary genital syphilis
 ;;^UTILITY(U,$J,358.3,1363,1,4,0)
 ;;=4^A51.0
 ;;^UTILITY(U,$J,358.3,1363,2)
 ;;=^5000272
 ;;^UTILITY(U,$J,358.3,1364,0)
 ;;=A52.3^^3^41^80
 ;;^UTILITY(U,$J,358.3,1364,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1364,1,3,0)
 ;;=3^Neurosyphilis, unspecified
 ;;^UTILITY(U,$J,358.3,1364,1,4,0)
 ;;=4^A52.3
 ;;^UTILITY(U,$J,358.3,1364,2)
 ;;=^5000298
 ;;^UTILITY(U,$J,358.3,1365,0)
 ;;=A52.9^^3^41^78
 ;;^UTILITY(U,$J,358.3,1365,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1365,1,3,0)
 ;;=3^Late syphilis, unspecified
 ;;^UTILITY(U,$J,358.3,1365,1,4,0)
 ;;=4^A52.9
 ;;^UTILITY(U,$J,358.3,1365,2)
 ;;=^5000308
 ;;^UTILITY(U,$J,358.3,1366,0)
 ;;=A53.9^^3^41^98
 ;;^UTILITY(U,$J,358.3,1366,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1366,1,3,0)
 ;;=3^Syphilis, unspecified
 ;;^UTILITY(U,$J,358.3,1366,1,4,0)
 ;;=4^A53.9
 ;;^UTILITY(U,$J,358.3,1366,2)
 ;;=^5000310
 ;;^UTILITY(U,$J,358.3,1367,0)
 ;;=A54.00^^3^41^64
 ;;^UTILITY(U,$J,358.3,1367,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1367,1,3,0)
 ;;=3^Gonococcal infection of lower genitourinary tract, unsp
 ;;^UTILITY(U,$J,358.3,1367,1,4,0)
 ;;=4^A54.00
 ;;^UTILITY(U,$J,358.3,1367,2)
 ;;=^5000311
 ;;^UTILITY(U,$J,358.3,1368,0)
 ;;=B35.1^^3^41^99
 ;;^UTILITY(U,$J,358.3,1368,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1368,1,3,0)
 ;;=3^Tinea unguium
 ;;^UTILITY(U,$J,358.3,1368,1,4,0)
 ;;=4^B35.1
 ;;^UTILITY(U,$J,358.3,1368,2)
 ;;=^119748
 ;;^UTILITY(U,$J,358.3,1369,0)
 ;;=B37.3^^3^41^28
 ;;^UTILITY(U,$J,358.3,1369,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1369,1,3,0)
 ;;=3^Candidiasis of vulva and vagina
 ;;
 ;;$END ROU IBDEI041
